OakChart

Oruka Therapeutics Inc

ORKAHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 3:59 PM ET

107.17-2.33 (-2.13%)
2026-11-11 22:09 CET
Market cap
7,249.96 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-152.57 USD m
Free cash flow, TTM
-123.86 USD m
EPS diluted, TTM
-2.47
P/E
-
Compare

Price

ORKA against its 20, 50 and 200-day averages
2050200miss
40.0060.0080.00100.00120.002.4M4.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ORKAclose 107.1720-day 91.6450-day 89.12200-day 71.95107.1752w high

7.2% under the 52-week high of 115.52 on 19 Aug 2026. 52-week low 25.23 on 5 Jan 2026. Last 15 sessions, 44.5% high to low

Volume 0.89× normal · the line is the 50-bar volume average

Profile

ORKA
52-week range, 91% of the way up
25.23115.51

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

IndexRUT
Employees68
IPOAug 08, 1997
Beta-0.36
ATR, 14d5.69
Rel volume0.89
Short float11.00%
Insider own11.21%
Inst own103.35%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap7.27B
Enterprise Value6.35B
Income-152.57M
Sales0.00M
Book/sh17.78
Cash/sh13.57
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees68
IPOAug 08, 1997

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B6.03
P/C7.90
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio29.62
Current Ratio29.62
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.47
EPS next Y-2.95
EPS next Q-0.75
EPS this Y-37.83%
EPS next Y-15.72%
EPS next 5Y-26.32%
EPS past 3/5Y34.61% 37.79%
Sales past 3/5Y- -
EPS Y/Y TTM-2.35%
Sales Y/Y TTM-
EPS Q/Q-1.57%
Sales Q/Q-
EarningsNov 09 AMC
EPS/Sales Surpr.-5.07% -

Ownership

Insider Own11.21%
Insider Trans-35.09%
Inst Own103.35%
Inst Trans47.34%
ROA-17.53%
ROE-18.12%
ROIC-12.72%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2016.95%
SMA5020.25%
SMA20048.95%
Trades-

Technical

Shs Outstand67.23M
Shs Float58.79M
Short Float11.00%
Short Ratio6.83
Short Interest6.46M
52W High115.51 -7.22%
52W Low25.23 324.77%
Volatility7.27% 5.92%
ATR (14)5.69
RSI (14)67.76
Beta-0.36
Rel Volume0.89
Avg Volume946.67K
Volume843,603

Performance

Perf Week5.68%
Perf Month37.06%
Perf Quarter-0.88%
Perf Half Y69.63%
Perf YTD253.58%
Perf Year280.04%
Perf 3Y826.24%
Perf 5Y586.18%
Perf 10Y-60.74%
Recom1.07
Target Price152.23
Prev Close109.50
Price107.17
Change %-2.13%

Analyst ratings

latest 10 of 13
DateActionAnalystRating changeTargetImplied
Dec 18, 2025InitiatedPPiper SandlerOverweight$75-30.0%
Nov 13, 2025InitiatedJJefferiesBuy$45-58.0%
Oct 27, 2025InitiatedGGuggenheimBuy$60-44.0%
Oct 13, 2025InitiatedBBarclaysOverweight$48-55.2%
May 22, 2025InitiatedBBTIG ResearchBuy$44-58.9%
Feb 04, 2025InitiatedWWolfe ResearchOutperform$20-81.3%
Oct 11, 2024InitiatedSStifelBuy$49-54.3%
Oct 07, 2024InitiatedHH.C. WainwrightBuy$45-58.0%
Sep 17, 2024InitiatedLLeerink PartnersOutperform$44-58.9%
Sep 16, 2024InitiatedTTD CowenBuy

Peers

Mkt cap
TickerCompanyMkt cap
PTGXProtagonist Therapeutics Inc8.80B
MLTXMoonLake Immunotherapeutics1.15B
SYRESpyre Therapeutics Inc10.14B
ALMSAlumis Inc883.74M
ARQTArcutis Biotherapeutics Inc3.59B
KYMRKymera Therapeutics Inc11.51B
JBIOJade Biosciences Inc1.05B
ACRSAclaris Therapeutics Inc688.38M
ATTOAttovia Therapeutics Inc764.77M
JNJJohnson & Johnson674.84B

Insider trading

latest 14 of 93
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Klein Lawrence OttoChief Executive OfficerNov 02 '26Option Exercise7.8025,000195,000948,128Nov 02 05:46 PM
Klein Lawrence OttoChief Executive OfficerNov 02 '26Sale95.6025,0002,390,125923,128Nov 02 05:46 PM
LAWRENCE KLEINDirectorNov 02 '26Proposed Sale96.8725,0002,421,750Nov 02 04:39 PM
Quinlan Paul TGeneral CounselOct 20 '26Option Exercise7.809,00070,20038,995Oct 20 08:42 PM
Quinlan Paul TGeneral CounselOct 20 '26Sale78.539,000706,73529,995Oct 20 08:42 PM
Goncalves JoanaChief Medical OfficerOct 15 '26Option Exercise7.327,00051,24038,771Oct 15 06:15 PM
Goncalves JoanaChief Medical OfficerOct 15 '26Sale74.817,000523,64831,771Oct 15 06:15 PM
JOANA GONCALVESOfficerOct 15 '26Proposed Sale76.6821,0001,610,280Oct 15 04:38 PM
Agarwal ArjunSenior Vice President, FinanceOct 12 '26Option Exercise15.699,999156,90324,218Oct 13 04:34 PM
Agarwal ArjunSenior Vice President, FinanceOct 12 '26Sale80.609,999805,88914,219Oct 13 04:34 PM
Arjun AgarwalOfficerOct 12 '26Proposed Sale82.119,999821,018Oct 13 08:24 AM
Klein Lawrence OttoChief Executive OfficerOct 01 '26Option Exercise7.8025,000195,000948,128Oct 02 07:54 PM
Klein Lawrence OttoChief Executive OfficerOct 01 '26Sale83.6225,0002,090,593923,128Oct 02 07:54 PM
LAWRENCE KLEINDirectorOct 01 '26Proposed Sale83.2925,0002,082,250Oct 01 04:22 PM

Held by

AUM
TickerCompanyAUM
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B

News

latest 14 of 200
  • Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • Oruka Therapeutics to Participate in Multiple Upcoming Conferences (GlobeNewswire)
  • Orukas Psoriasis Treatment Could Generate $7B In Peak Sales, Says Guggenheim ORKA Stock Heads For Best Day In Over 4 Months (Stocktwits) +12.70%
  • Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis (GlobeNewswire)
  • Stocktwits Pharma Pulse: Big Pharma Earnings, Cancer Updates And 2 FDA Deadlines The Weeks Biotech Watchlist (Stocktwits)
  • Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026 (GlobeNewswire)
  • Oruka Therapeutics Shares Fall 5% After Week 28 ORKA-001 Trial Data (InvestorsHub)
  • Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing (GlobeNewswire)
  • Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference (GlobeNewswire)
  • Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer (GlobeNewswire) -5.13%
  • Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) +6.40%
  • HMI Capital Pares Its Stake in AI Company nCino (Barrons.com)
  • Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
  • Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.630-0.600-0.6530.000.0012
2026Q22026-08-10-0.550-0.513-0.6550.000.0012
2026Q12026-05-13-0.480-0.547-0.5770.000.0012
2025Q42026-03-12-0.450-0.636-0.5440.000.0011
2025Q32025-11-12-0.550-0.577-0.6870.000.009
2025Q22025-08-11-0.460-0.490-0.5840.000.007
2025Q12025-05-14-0.400-0.508-0.5040.000.006
2024Q42025-03-06-0.490-0.682-0.6420.000.007
2024Q32024-11-13-1.460-0.402-1.9070.000.006
2024Q22024-08-01-14.162--2.2150.00--
2024Q12024-04-25---1.663---
2023Q32023-10-18---1.186---
2023Q22023-07-21---1.233---
2023Q12023-04-24---1.121---
2022Q32022-10-28---1.943---
2022Q22022-08-02---2.621---

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2016FY-390.96--390.96--
2017FY-382.32-421.2-382.870.000.00
2018FY-123.12-131.76-123.730.000.00
2019FY-4.150-4.420-49.7900.000.00
2020FY-24.840--24.809--
2024FY-3.911-3.409-4.9870.000.00
2025FY-1.850-2.204-1.9400.000.00
2026FY--2.550--0.00
2027FY--2.951--0.00
2028FY--3.729--0.00
2029FY--4.117--0.00
2030FY--4.243--155.91

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-107000.000.000.00
2026Q4S2026-11-096000.000.000.00
2026Q4S2026-08-256000.000.000.00
2026Q4S2026-08-225000.000.000.00
2026Q4S2026-08-106000.000.000.00
2026Q4S2026-07-236000.000.000.00
2026Q4S2026-05-147000.000.000.00
2026Q4S2026-04-108000.000.000.00
2026Q4S2026-03-137000.000.000.00
2026Q4S2025-12-177000.000.000.00
2026Q4S2025-11-136000.000.000.00
2026Q4S2025-11-115000.000.000.00
2026Q4S2025-11-105000.000.000.00
2026Q4S2025-11-095000.000.000.00

Estimate history

EPS, annual-382.867-123.729-49.79-24.809-16.676-8.266-4.444-4.987-2.311-2.4737
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.907-0.642-0.504-0.584-0.687-0.544-0.577-0.655-0.698
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.0550.0640.1330.7961.2011.2011.20837.44148.72267.228
Period201720182019202020212022202320242025MRQ
Shares, quarterly34.99937.44137.44137.45148.38448.72250.16861.0767.228
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.160.080.030.110.110.090.090.090.02
Gross Profit-0.16-0.08-0.03-0.11-0.11-0.09-0.09-0.09-0.02
Selling, General and Administrative Excl. Other182.94121.9788.107.189.7319.249.675.728.10
Research and Development153.74100.6475.061.014.4613.834.991.834.24
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-183.11-122.05-88.12-7.30-9.84-19.34-9.77-5.81-8.12
Interest Expense0.000.001.470.000.000.000.010.010.00
Unusual Expense0.000.000.000.000.76----
Net Income Before Taxes-152.57-105.43-83.72-5.34-9.93-19.32-9.75-5.65-7.96
Income Taxes0.000.000.000.000.000.00-0.01-0.17-0.03
Consolidated Net Income-152.57-105.43-83.72-5.34-9.93-19.32-9.74-5.48-7.93
Net Income From Continuing Operations-152.57-105.43-83.72-5.34-9.93-19.32-9.74-5.48-7.93
Net Income-152.57-105.43-83.72-5.34-9.93-19.32-9.74-5.48-7.93
EPS (Recurring)-2.13-2.31-4.99-4.44-7.83-16.68-24.81-49.79-123.73
EPS (Basic, Before Extraordinaries)-2.47-2.31-4.99-4.44-8.27-16.68-24.81-49.79-123.73
EPS (Diluted)-2.47-2.31-4.99-4.44-8.27-16.68-24.81-49.79-123.73
EBITDA-182.94-121.97-88.10-7.18-9.73-19.24-9.67-5.72-8.10
Non-Operating Income (Expense)30.5316.625.871.960.670.010.030.170.15
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense27.5024.2423.930.690.560.500.030.110.22
Shares Outstanding67.2348.7237.441.211.201.200.800.130.06
Market Capitalization7,249.967,249.96678.6213.1818.3716.6620.594.902.50

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.050.040.040.030.020.020.020.02
Gross Profit-0.05-0.04-0.04-0.03-0.02-0.02-0.02-0.02
Selling, General and Administrative Excl. Other62.0950.0636.3934.4034.0928.4125.0730.30
Research and Development53.7043.2629.1427.6428.9924.0919.9325.50
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-62.14-50.11-36.43-34.43-34.10-28.43-25.09-30.32
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-49.97-41.21-31.82-29.58-30.28-24.57-21.00-25.78
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-49.97-41.21-31.82-29.58-30.28-24.57-21.00-25.78
Net Income From Continuing Operations-49.97-41.21-31.82-29.58-30.28-24.57-21.00-25.78
Net Income-49.97-41.21-31.82-29.58-30.28-24.57-21.00-25.78
EPS (Recurring)-0.70-0.66-0.58-0.54-0.69-0.58-0.50-0.64
EPS (Basic, Before Extraordinaries)-0.70-0.66-0.58-0.54-0.69-0.58-0.50-0.64
EPS (Diluted)-0.70-0.66-0.58-0.54-0.69-0.58-0.50-0.64
EBITDA-62.09-50.06-36.39-34.40-34.09-28.41-25.07-30.30
Non-Operating Income (Expense)12.178.904.614.853.833.854.094.54
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense9.137.286.974.1210.165.084.8814.16
Shares Outstanding67.2361.0750.1748.7248.3837.4537.4437.44
Market Capitalization7,249.965,739.902,430.071,467.28930.43419.71384.14678.62

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments337.04375.6537.4342.4553.3649.078.366.6111.75
Short Term Receivables0.000.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets6.811.220.160.251.060.900.120.170.55
Total Current Assets343.86376.8737.5942.7054.4249.978.486.7812.30
Net Property, Plant & Equipment2.121.040.260.370.480.450.030.020.04
Total Investments and Advances142.5418.070.000.000.000.000.000.000.00
Intangible Assets---0.000.000.000.000.000.00
Other Assets0.100.040.010.020.020.010.020.020.02
Total Assets488.62396.0237.8643.0954.9250.438.546.8312.37
Short Term Debt Incl. Current Port. of LT Debt0.620.210.080.100.100.040.030.000.00
Accounts Payable4.163.460.000.331.121.770.420.230.62
Other Current Liabilities10.609.370.560.692.281.690.480.561.45
Total Current Liabilities15.3713.040.641.133.503.500.930.792.07
Long Term Debt1.310.760.200.280.380.410.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.000.02
Total Liabilities16.6913.800.841.413.883.910.930.792.09
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value2.932.930.000.000.000.000.000.000.00
Common Equity469.00379.2937.0241.6751.0446.527.616.0310.28
Total Shareholders Equity471.93382.2237.0241.6751.0446.527.616.0310.28
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity471.93382.2237.0241.6751.0446.527.616.0310.28
Total Liabilities & Stockholders Equity488.62396.0237.8643.0954.9250.438.546.8312.37
Book Value Per Share9.6310.1330.6334.7042.5158.4757.2993.57188.48
Tangible Book Value Per Share9.6310.1330.6334.7042.5158.4757.2993.57188.48
Full-Time Employees6828561914131520
Price to Book Ratio6.162.000.350.430.330.440.640.410.59
Return on Assets-23.84-38.59-13.19-20.26-36.68-33.03-71.38-82.68-99.96
Return on Equity-24.69-39.94-13.57-21.41-39.61-35.98-80.37-97.30-113.89
Return on Invested Capital-22.28-21.86-14.34-23.66-37.57-20.75-72.04-131.52-179.95
Quick Ratio22.3728.8959.0137.7215.5614.289.168.555.94
Current Ratio22.3728.8959.0137.7215.5614.289.168.555.94

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-152.57-105.43-83.72-5.34-9.93-19.32-9.74-5.48-7.93
Depreciation0.160.080.030.110.110.090.090.090.02
Other Funds (Non Cash)24.0619.7014.270.690.560.500.040.150.28
Funds from Operations-128.35-85.66-69.43-4.54-9.25-18.73-9.60-5.24-7.64
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital4.71-2.5611.59-0.47-1.66-0.031.880.44-0.61
Cash from Operating Activities-123.64-88.21-57.84-5.01-10.91-18.76-7.72-4.80-8.24
Capital Expenditures-0.22-0.21-0.190.00-0.00-0.04-0.02-0.00-0.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-606.59-96.54-329.940.000.000.000.000.003.05
Purchase of Investments-1,011.87-520.96-329.94-0.000.000.000.000.00
Sale Or Maturity of Investments405.29424.420.000.000.000.000.000.003.05
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-606.80-96.75-330.130.00-0.00-0.04-0.02-0.003.05
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock830.71170.31449.540.000.0023.0948.866.913.42
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock830.71170.31449.540.000.0023.0948.866.913.42
Proceedsfrom Stock Options820.36170.31449.540.000.0023.0948.866.913.42
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00-0.41-0.350.00
Change in Long Term Debt0.000.000.000.000.000.00-0.41-0.350.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00-0.41-0.350.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00-0.31
Other Financing Activities Uses0.000.000.000.000.000.000.000.00-0.31
Cash from Financing Activities830.71170.31449.540.000.0023.0948.456.563.10
Net Change in Cash100.27-14.6461.58-5.01-10.914.2940.711.75-2.09
Free Cash Flow-123.86-88.42-58.03-5.01-10.91-18.80-7.74-4.80-8.25
Preferred Dividends (Cash Flow)---0.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments920.28873.56388.83337.04349.15328.41
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets21.2210.996.426.816.013.61
Total Current Assets941.49884.56395.25343.86355.16332.01
Net Property, Plant & Equipment3.102.692.002.122.222.25
Total Investments and Advances286.31252.02107.12142.54151.7623.05
Other Assets0.130.130.100.100.100.10
Total Assets1,231.031,139.39504.48488.62509.25357.42
Short Term Debt Incl. Current Port. of LT Debt0.840.670.680.620.420.66
Accounts Payable14.387.953.664.162.214.66
Other Current Liabilities16.5714.3512.2910.6018.346.79
Total Current Liabilities31.7822.9716.6315.3720.9712.11
Long Term Debt2.091.881.131.311.491.67
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities33.8824.8417.7616.6922.4613.78
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value2.022.932.932.932.932.93
Common Equity1,195.131,111.62483.79469.00483.86340.71
Total Shareholders Equity1,197.151,114.55486.72471.93486.79343.64
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1,197.151,114.55486.72471.93486.79343.64
Total Liabilities & Stockholders Equity1,231.031,139.39504.48488.62509.25357.42
Book Value Per Share17.7818.209.649.6310.009.10
Tangible Book Value Per Share17.7818.209.649.6310.009.10
Full-Time Employees---68--
Price to Book Ratio6.169.875.103.032.111.16
Return on Assets-17.53-17.76-26.37-23.84-22.01-51.10
Return on Equity-18.12-18.23-27.31-24.69-23.05-53.15
Return on Invested Capital-4.17-3.69-6.52-6.25-6.20-7.12
Quick Ratio29.6238.5123.7622.3716.9427.42
Current Ratio29.6238.5123.7622.3716.9427.42

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-49.97-41.21-31.82-29.58-30.28-24.57
Depreciation0.050.040.040.030.020.02
Other Funds (Non Cash)7.326.486.673.599.263.70
Funds from Operations-42.59-34.69-25.11-25.96-21.00-20.86
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.731.541.533.37-0.60-2.29
Cash from Operating Activities-44.33-33.15-23.58-22.59-21.60-23.14
Capital Expenditures-0.080.00-0.07-0.06-0.10-0.03
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-159.32-410.95-14.36-21.96-122.354.89
Purchase of Investments-329.50-490.55-90.83-100.99-267.68-108.00
Sale Or Maturity of Investments170.1979.6076.4779.03145.33112.89
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-159.40-410.95-14.44-22.02-122.454.86
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.00---0.00-
Change in Capital Stock126.77663.0440.600.30169.910.11
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock126.77663.0440.600.30169.910.11
Proceedsfrom Stock Options122.48658.6738.900.30169.910.11
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities126.77663.0440.600.30169.910.11
Net Change in Cash-76.95218.952.58-44.3225.86-18.18
Free Cash Flow-44.41-33.15-23.65-22.66-21.70-23.18

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3011.00%6.5M58.8M890.20K
2026-10-1510.40%6.1M58.8M900.49K
2026-09-3013.23%7.8M58.8M991.72K
2026-09-1512.97%7.6M58.8M1.13M
2026-08-3113.26%7.8M58.8M1.21M
2026-08-1414.78%8.3M56.2M1.29M
2026-07-3115.85%8.1M50.8M1.46M
2026-07-1517.39%8.8M50.8M1.78M
2026-06-3018.03%9.2M50.8M1.76M
2026-06-1513.58%6.9M50.8M1.55M
2026-05-2912.56%6.4M50.8M1.45M
2026-05-1512.32%6.3M50.8M1.31M
2026-04-3013.90%7.0M50.3M1.08M
2026-04-1513.30%5.5M41.7M687.47K
2026-03-3110.82%4.5M41.8M537.87K
2026-03-138.72%3.6M41.8M529.93K
2026-02-2710.93%4.5M40.9M510.98K
2026-02-139.94%4.1M40.9M528.56K
2026-01-3011.53%4.9M42.6M548.53K
2026-01-1512.28%5.2M42.7M503.33K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call15.0090.6095.5020.2210.3830.000.000.998-0.0270.001
call17.5088.2093.0033.109.9910.000.000.990-0.1580.004
call20.0085.6090.5019.008.7401.000.000.978-0.3810.009
call22.5083.2088.000.008.5270.000.000.982-0.2650.007
call25.0080.5085.400.007.5580.000.000.973-0.3860.010
call30.0075.6080.5055.006.9750.000.000.977-0.2670.009
call35.0070.9075.5047.646.18561.000.000.974-0.2660.010
call40.0065.9070.500.005.5180.000.000.970-0.2640.011
call45.0060.9065.5010.504.9402.000.000.966-0.2610.013
call50.0055.9060.5015.604.4302.000.000.962-0.2570.014
call55.0050.9055.500.003.9720.000.000.957-0.2530.015
call60.0045.9050.5038.003.5554.000.000.952-0.2470.017
call65.0040.9045.5017.603.17121.000.000.946-0.2410.018
call70.0035.9040.5019.302.81313.000.000.938-0.2350.020
call75.0030.9035.505.002.47834.000.000.929-0.2260.023
call80.0026.0030.1027.971.73522.000.000.919-0.2170.025
call85.0021.0025.2012.541.46926.000.000.905-0.2060.028
call90.0016.5019.5015.201.3327.000.000.885-0.1920.032
call95.0012.3015.2011.831.2043.000.000.749-0.4250.053
call1008.7012.4013.001.12027.005.000.684-0.3950.059
call1055.607.908.000.9272,16463.000.585-0.3730.065
call1102.456.604.251.2026026010.478-0.4270.066
call1150.654.902.001.1905644360.385-0.4250.064
call1200.901.851.851.2741411.000.321-0.4340.060
call1250.201.701.300.9423.003.000.166-0.2240.042
call1300.001.751.101.09443.000.000.148-0.2410.039
call1350.003.603.901.2344.000.000.136-0.2550.036
call1400.003.609.331.4062.000.000.144-0.3020.038
call1450.003.500.001.5350.000.000.135-0.3140.037
call1500.003.500.751.6021120.000.111-0.2880.032
call1550.003.500.001.7650.000.000.122-0.3360.034
call1600.003.500.001.8710.000.000.116-0.3450.033
call1650.003.500.001.9130.000.000.097-0.3110.029
put15.000.000.051.7510.3352.000.00-0.022-0.4890.009
put17.500.000.502.359.4371.000.00-0.025-0.5050.010
put20.000.003.400.008.6990.000.00-0.028-0.5160.012
put22.500.003.404.008.2131.000.00-0.031-0.5440.012
put25.000.003.400.007.6600.000.00-0.034-0.5490.013
put30.000.003.400.006.7350.000.00-0.041-0.5540.015
put35.000.003.400.005.9790.000.00-0.047-0.5550.017
put40.000.003.402.004.0521.000.00-0.030-0.2590.011
put45.000.003.402.003.61113.000.00-0.034-0.2560.013
put50.000.003.409.703.2192.000.00-0.038-0.2510.014
put55.000.003.409.003.8792.000.00-0.076-0.5270.025
put60.000.003.4013.753.4800.000.00-0.085-0.5140.027
put65.000.003.400.103.0711.000.00-0.098-0.4990.029
put70.000.003.403.102.7271.000.00-0.111-0.4820.032
put75.000.003.006.002.41823.000.00-0.124-0.4510.037
put80.000.003.500.552.22512.000.00-0.151-0.4880.040
put85.000.003.500.321.23429.000.00-0.095-0.1960.028
put90.000.001.701.001.00345.0010.00-0.115-0.1820.032
put95.000.553.901.101.39033.001.00-0.251-0.4140.053
put1000.704.402.451.1664.001.00-0.318-0.3960.060
put1052.155.803.701.04619.000.00-0.415-0.3620.065
put1104.808.1020.800.9882.000.00-0.522-0.4140.066
put1157.7011.6024.101.0290.000.00-0.655-0.3210.061
put12011.6015.400.001.0470.000.00-0.679-0.4200.060
put12516.5020.000.001.1580.000.00-0.834-0.2100.042
put13020.6025.0033.001.2150.000.00-0.852-0.2260.039
put13525.0029.400.001.3390.000.00-0.864-0.2400.036
put14030.0034.400.001.4760.000.00-0.874-0.2520.034
put14535.0039.700.001.6310.000.00-0.861-0.3200.037
put15040.0044.500.001.7530.000.00-0.868-0.3310.036
put15544.8049.500.001.8690.000.00-0.874-0.3420.034
put16050.0054.500.001.9790.000.00-0.879-0.3510.033
put16555.0059.500.002.0840.000.00-0.884-0.3600.033

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-02144Filing for proposed sale of securities under Rule 144.SEC
2026-11-024Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-10-268-KCurrent report2026-10-26SEC
2026-10-204Statement of changes in beneficial ownership of securities2026-10-20SEC
2026-10-15144Filing for proposed sale of securities under Rule 144.SEC
2026-10-154Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-13144Filing for proposed sale of securities under Rule 144.SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-21144Filing for proposed sale of securities under Rule 144.SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-28424B5SEC
2026-08-27EFFECTEffectiveness filing by commission orderSEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-24SEC
2026-08-253Initial statement of beneficial ownership of securities2026-08-24SEC
2026-08-248-KCurrent report2026-08-24SEC
2026-08-21S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-17SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11002.39M1
2026-10004.13M4
2026-090010.42M10
2026-08007.49M3
2026-0700301.94M4
2026-06004.03M9
2026-05007.55M4
2026-0400462.83K1
2026-0300623.16K6
2026-0200226.56K1
2026-0100593.50K2
2025-1200214.29K1
2025-110000

Institutional holders

Manager% owned
FMR LLC15.33%
BlackRock, Inc.8.27%
Venrock Adviser, LLC6.88%
Fairmount Funds Management LLC6.14%
Capital World Investors5.64%
RTW INVESTMENTS, LP5.20%
STATE STREET CORP4.43%
VANGUARD CAPITAL MANAGEMENT LLC3.91%
Paradigm Biocapital Advisors LP3.56%
Deep Track Capital, LP3.19%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.86%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.58%
SMALLCAP World Fund Inc2.53%
iShares Russell 2000 ETF2.16%
New Economy Fund2.00%
Fidelity Growth Company Fund1.95%
Select Health Care Portfolio1.33%
Fidelity Advisor Biotechnology Fund1.22%
Fidelity Small Cap Growth Fund1.14%
VANGUARD EXTENDED MARKET INDEX FUND0.96%

OakChart. ORKA. Cached 15 minutes.